If metformin’s mechanism of action is dependent on the LKB1-AMPK-ACC pathway, it would be expected that chronic metformin treatment would alleviate nonalcoholic fatty liver disease (NAFLD). This evidence concerns the gene STK11 and metabolic dysfunction-associated steatotic liver disease.